Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer - Impact on recurrence and survival

被引:110
作者
Gu, CD
Osaki, T
Oyama, T
Inoue, M
Kodate, M
Dobashi, K
Oka, T
Yasumoto, K
机构
[1] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan
[2] Kitakyushu Municipal Med Ctr, Dept Resp Surg, Kitakyushu, Fukuoka, Japan
[3] Natl Oita Hosp, Dept Resp Surg, Oita, Japan
关键词
D O I
10.1097/00000658-200201000-00017
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective To detect occult micrometastatic tumor cells in pNO lymph nodes of nonsmall cell lung cancer (NSCLC) by a combination of cytokeratin and p53 immunohistochemistry staining, and to evaluate the relation between the micrometastasis in pNO lymph nodes and the prognosis of patients with completely resected stage I NSCLC, Summary Background Data The average 5-year survival rate for patients with completely resected stage 1 NSCLC is only about 70%; thus, about 30% of these patients have recurrent disease. This suggests that occult micrometastasis may exist at the time of surgery; the rate is clearly underestimated by current clinical staging examinations and conventional histopathologic methods. Methods A total of 474 hilar and mediastinal lymph nodes were removed during surgery from 49 patients with completely resected stage 1 NSCLC. The lymph nodes analyzed for micrometastasis using immunohistochemical staining with the biclonal anticytolkeratin antibody, AE1/AE3 Of these 474 lymph nodes from 49 patients, 263 lymph nodes from 25 patients, whose primary tumors were positive for the p53 protein, were subjected to immunohistochemical staining with the monoclonal anti-p53 protein antibody DO-1. Results Cells positive for cytokeratin and p53 protein were found in 35 (7.4%) of 474 and 20 (7.6%) of 263 lymph nodes, respectively; 17 (34.7%) of 49 patients had cytokeratin-positive cells and 10 (40.0%) of 25 patients had p53-positive cells in their pNO lymph nodes. By a combination of cytokeratin and p53 protein immunohistochemical staining, micrometastatic tumor cells were identified in pNO lymph nodes in 22 (44.9%) of 49 patients. The patients with lymph node micrometastasis identified by a combination of cytokeratin and p53 protein immunohistochemical staining had a poorer prognosis than those without micrometastasis on both univariate and multivariate analyses (overall survival, P = .0003 and 0.013, respectively). Conclusions The detection of lymph nodal micrometastasis by cytokeratin and p53 protein immunohistochemical staining will be helpful to predict the recurrence and prognosis of patients with completely resected stage 1 NSCLC.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 29 条
[1]  
BRAMBILLA E, 1993, AM J PATHOL, V143, P199
[2]   FREQUENCY AND DISTRIBUTION OF OCCULT MICROMETASTASES IN LYMPH-NODES OF PATIENTS WITH NON-SMALL-CELL LUNG-CARCINOMA [J].
CHEN, ZL ;
PEREZ, S ;
HOLMES, EC ;
WANG, HJ ;
COULSON, WF ;
WEN, DR ;
COCHRAN, AJ .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (06) :493-498
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: Prognostic significance [J].
Dobashi, K ;
Sugio, K ;
Osaki, T ;
Oka, T ;
Yasumoto, K .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (03) :339-346
[5]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[6]   CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE [J].
HARRIS, CC ;
HOLLSTEIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (18) :1318-1327
[7]  
ISIDA T, 1993, CANCER RES, V53, P5000
[8]   Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: Significance of nodal micrometastasis [J].
Izbicki, JR ;
Passlick, B ;
Hosch, SB ;
Kubuschock, B ;
Schneider, C ;
Busch, C ;
Knoefel, WT ;
Thetter, O ;
Pantel, K .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 112 (03) :623-630
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]   C-ERBB-2 EXPRESSION AND CODON 12-K-RAS MUTATIONS BOTH PREDICT SHORTENED SURVIVAL FOR PATIENTS WITH PULMONARY ADENOCARCINOMAS [J].
KERN, JA ;
SLEBOS, RJC ;
TOP, B ;
RODENHUIS, S ;
LAGER, D ;
ROBINSON, RA ;
WEINER, D ;
SCHWARTZ, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :516-520